AllDocs -> cancers

lymphoma Etanercept (Enbrel®) Safety Review March 4, 2003 Presentation Outline Introduction Dan Burge, MD Etanercept Clinical Profile Pharmacovigilance General Safety Malignancy/ Lymphoma Epidemiology of Lymphoma in RA Alan Silman, MD Lymphoma and Etanercept Dan Burge, MD Heart Failure Experience Ongoing Pharmacovigilance Summary C2 Consultants Jeffrey Borer, MD Division of Cardiology The New York Hospital Cornell University Medical Center New York, New York Mary K. Crow, MD Dept. of Rheumatology Cornell University Hospital for Special Surgery New York, New York Annette Langer-Gould, MD Dept. of Health Research and Policy Stanford ...

Transformation of follicular lymphoma to diffuse large-cell lymphoma : Alternative patterns with increased or decreased expression of c-myc and its regulated genes Izidore S. Lossos* † , Ash A. Alizadeh †‡ , Maximilian Diehn ‡ , Roger Warnke § , Yvonne Thorstenson ¶ , Peter J. Oefner ¶ , Patrick O. Brown ‡ , David Botstein**, and Ronald Levy* †† Division of Oncology, Departments of *Medicine, ‡ Biochemistry, § Pathology, and **Genetics, ¶ Stanford Genome Technology Center, and Howard Hughes Medical Institute, Stanford University Medical Center, Stanford, CA 94305-5306 Contributed by David Botstein, April 29, 2002 The natural history of follicular lymphoma (FL) is frequently char- ...

44 P&T ® • January 2003 • Vol. 28 No. 1 A one-day workshop, entitled “Innovations in Lymphoma Treatments,” was held on Novem- ber 16, 2002, in New York City. The sessions provided a forum for patients, caregivers, and clinicians to learn about current and future clinical tri- als in lymphoma research. The workshop also provided an opportunity to gain knowledge of the promising new therapies under clinical investigation and to reflect on the combination of currently approved therapies with new drug classes to treat follicular B-cell non-Hodgkin’s lymphoma (NHL) and other lymphomas. This is an era of exciting new de- velopments in drugs and biologicals for the therapy of NHL; breakthroughs will eventually prolong the lives of patients of all ages with the disease. A new age of lymphoma therapy began in 1997 with the ap- proval of rituximab ...

QC Form 0451 Ambion, Inc. • Austin, TX USA • US Toll-free Tel: 800-888-8804 • International Tel: +1 512 651 0200 Ambion (Europe) Ltd • Huntingdon, Cambridgeshire, UK • International Tel: +44 1480 373020 For complete contact and distributor information, see: www.ambion.com www.ambion.com/techlib/spec/sp_7863.pdf Catalog #: 7863 – 5 µ g Concentration: 0.5 mg/ml Absorbance A 260/280 : 1.7–2.1 Storage Conditions: THE RNA Storage Solution (1 mM Sodium Citrate, pH 6.4; Ambion, Inc. Cat #7000). Quality Control: Functional Analysis: All Human poly(A) RNAs undergo accelerated stability testing. RNA integrity is checked both before and after a 14–18 hour incubation at 37 ° C and is visualized on a 1% denaturing agarose gel. Poly(A) RNAs are functionally tested by Northern blot analysis using Ambion’s NorthernMax Kit (Catalog #1940) and an anti- ...

QC Form 0446 Ambion, Inc. • Austin, TX USA • US Toll-free Tel: 800-888-8804 • International Tel: +1 512 651 0200 Ambion (Europe) Ltd • Huntingdon, Cambridgeshire, UK • International Tel: +44 1480 373020 For complete contact and distributor information, see: www.ambion.com www.ambion.com/techlib/spec/sp_7856.pdf Catalog #: 7856 – 100 µ g Concentration: 1 mg/ml Absorbance A 260/280 : 1.7–2.1 Storage Conditions: THE RNA Storage Solution (1 mM Sodium Citrate, pH 6.4; Ambion, Inc. Cat #7000). Quality Control: Nonspecific Endonuclease/Nickase Activity: None detected after a 14–16 hour incubation of 1 µ g of RNA with 300 ng of supercoiled plasmid DNA, analyzed on an agarose gel. Exonuclease Activity: None detected after a 14–16 hour incubation of 1 µ g of RNA with 40 ng of 32 P-labeled Sau 3A fragments of pUC19, ...

QC Form 0450 Ambion, Inc. • Austin, TX USA • US Toll-free Tel: 800-888-8804 • International Tel: +1 512 651 0200 Ambion (Europe) Ltd • Huntingdon, Cambridgeshire, UK • International Tel: +44 1480 373020 For complete contact and distributor information, see: www.ambion.com www.ambion.com/techlib/spec/sp_7862.pdf Catalog #: 7862 – 100 µ g Concentration: 1 mg/ml Absorbance A 260/280 : 1.7–2.1 Storage Conditions: THE RNA Storage Solution (1 mM Sodium Citrate, pH 6.4; Ambion, Inc. Cat #7000). Quality Control: Nonspecific Endonuclease/Nickase Activity: None detected after a 14–16 hour incubation of 1 µ g of RNA with 300 ng of supercoiled plasmid DNA, analyzed on an agarose gel. Exonuclease Activity: None detected after a 14–16 hour incubation of 1 µ g of RNA with 40 ng of 32 P-labeled Sau 3A fragments of pUC19, ...

QC Form 0447 Ambion, Inc. • Austin, TX USA • US Toll-free Tel: 800-888-8804 • International Tel: +1 512 651 0200 Ambion (Europe) Ltd • Huntingdon, Cambridgeshire, UK • International Tel: +44 1480 373020 For complete contact and distributor information, see: www.ambion.com www.ambion.com/techlib/spec/sp_7857.pdf Catalog #: 7857 – 5 µ g Concentration: 0.5 mg/ml Absorbance A 260/280 : 1.7–2.1 Storage Conditions: THE RNA Storage Solution (1 mM Sodium Citrate, pH 6.4; Ambion, Inc. Cat #7000). Quality Control: Functional Analysis: All Human poly(A) RNAs undergo accelerated stability testing. RNA integrity is checked both before and after 14–18 hour incubation at 37 ° C and is visualized on a 1% denaturing agarose gel. Poly(A) RNAs are functionally tested by Northern blot analysis using Ambion’s NorthernMax Kit (Cat #1940) and an anti-sense ...

Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts Ulf Klein 1 , Annunziata Gloghini 2 , Gianluca Gaidano 3 , Amy Chadburn 4 , Ethel Cesarman 4 , Riccardo Dalla-Favera 1 , and Antonino Carbone 2 1 Institute for Cancer Genetics, and the Departments of Pathology and Genetics & Development, Columbia University, New York, NY10032, U.S.A. 2 Division of Pathology and Medical Oncology A, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy 3 Hematology Unit, Division of Internal Medicine, Department of Medical Sciences & IRCAD, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy 4 Department of ...

Nuclear Medicine: Third of Lymphoma Patients in Remission with Bexxar - a smart isotope More than a third of lymphoma patients who had previously failed other therapy have no detectable signs of the disease three years after being treated with the experimental drug Bexxar, researchers said on Monday. Bexxar combines a natural immune system targeting agent with radiation therapy in the form of iodine 131, a radioactive isotope. The combination allows the tumor cells to receive a greater dose of radiation, while minimizing the amount of radiation affecting normal tissues, including delicate bone marrow. The drug is being developed by Coulter and SmithKline Beecham, which filed in September for U.S. Food and Drug Administration approval of the product. Research presented at a meeting of the American Society of Hematology in San Francisco showed that of 251 low-grade non-Hodgkin's lymphoma patients injected ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com Non-Hodgkin’s Lymphoma (NHL) and Exposure to Ionizing Radiation 1 Non-Hodgkin’s Lymphoma (NHL) and (Lymphosarcoma and reticulum cell sarcoma) Exposure to Ionizing Radiation Summary : Some evidence has been recorded of a possible connection between non-Hodgkin's lymphoma and exposure to ionizing radiation. There is possible evidence from studies conducted at Los Alamos National Laboratory. Studies of nuclear workers at other sites who have been exposed to ionizing radiation and persons exposed to the atomic bomb show an increase risk of developing non-Hodgkin's lymphoma . The National Research Council’s BEIR V committee did not address the issue of radiation- induced non-Hodgkin’s lymphoma . Non-Hodgkin's lymphoma is designated as a “specified” ...

L Y M P H O M A P A T I E N T G U I D E This brochure has been brought to you by 521 W. 57th St., 6th Floor New York, NY 10019 5300 McConnell Avenue Los Angeles, CA 90066 810 E. Hammond Lane Phoenix, AZ 85034 800-447-5816 © 2002IMPATH Inc. PS-BB-0302-74-00 Page 2 2 ] This booklet has been written to help patients and their families understand more about lymphomas – what they are, how they are diagnosed and how they are treated. This information is not intended to take the place of the advice of your doctor. Patients are strongly encouraged to talk to their physician for specific information on how their disease should be diagnosed, treated and followed. The first section deals with a description of lymphomas, their diagnosis and treatment. The second section provides ...

7 BACKGROUND INFORMATION ON NON-HODGKIN’S LYMPHOMA General Non-Hodgkin’s lymphomas (NHLs) encompass several unique malignant lymphoid disease entities that vary in clinical behavior, morphologic appearance, immunologic, and molecular phenotype. The various types represent neoplastic lymphoid cells arrested at different stages of normal differentiation. Based on their natural history, NHLs can be clinically classified as indolent, aggressive, and highly aggressive. Epidemiology NHLs are the fifth most common cause of cancer in the United States, with an estimated incidence of 63,600 cases in 2001 i . Follicular center cell lymphomas are the second most common subtype, comprising approximately 40% of all non-Hodgkin’s lymphomas. Since 1950, the incidence of NHL has steadily increased at approximately 4% per year. Classification Several histologic classifications ...

The Leukemia & Lymphoma Society Presents: TARGETED THERAPIES FOR LYMPHOMA October 23, 2002 National Transportation Safety Board Washington, DC W ELCOME & I NTRODUCTION Marshall Lichtman, MD The Leukemia & Lymphoma Society DR. LICHTMAN: Good evening, and welcome to all who are listening. My name is Marshall Lichtman. I'm the Executive Vice President for Research in Medical Programs of The Leukemia & Lymphoma Society and the Professor of Medicine at the University of Rochester Medical Center. The Leukemia & Lymphoma Society is pleased to be able to present an interactive teleconference entitled "Targeted Therapies for Lymphoma ." We would like to thank IDEC Pharmaceuticals Corporation for their generous sponsorship of this program. The Leukemia & Lymphoma Society’s mission includes ...

Targeted Therapies for Lymphoma For Health Care Professionals and Patients Workbook for the CME Teleconference Wednesday, October 23, 2002 6:00-8:00pm EDT This CE/CME activity is supported by an unrestricted educational grant from IDEC Pharmaceuticals Corporation. Page 2 T a r g e t e d T h e r a p i e s f o r L y m p h o m a An Interactive CME Teleconference – Wednesday, October 23, 2002 Table of Contents Welcome1 Agenda . 2 Participant Instructions . 3 CME Statement 4 Faculty . 5 Faculty Biographies 6 Advances in Immunotherapy for the Treatment of Lymphoma 9 Administration of Radioimmunotherapy and Side Effect Management . 28 CME Post Test Questions . 45 Post Test Answer Sheet & Activity Evaluation 48 This CE/CME activity is supported by an unrestricted ...

lymphoma 1. September 2002 Radioactive antibodies can cure lymphoma Pressinformation of the 15th Congress of the European Association of Nuclear Medicine by Ernst Jeroen Postema, Dept. of Nuclear Medicine, UMC Nijmegen, The Netherlands Treatment of Non-Hodgkin´s lymphoma with radioactive antibodies During the yearly congress of the European Association of Nuclear Medicine in Vienna a lot of attention will be paid to the treatment of non-Hodgkin?s lymphoma with radioactive antibodies. The results of this new treatment are so impressive, that one of those radioactive antibodies has been approved for clinical use in the United States this year. lymphoma cells react well For some decades researchers from all over the world have been trying to attach radioactive atoms to antibodies to treat cancer. These ?magic bullets? would go directly to the tumour cells ...

Johnhendrickfinal US Oncology PET Case Study – Lymphoma Courtesy of Dr. Galen Custer, Medical Oncologist – Kansas City Cancer Center Clinical Case Overview – Patient History: Patient had intermediate grade lymphoma in 1999. Persistent SPN early 2001 with no other evidence of disease. Why PET was ordered : This is the patient’s 1 st PET scan. It was ordered to evaluate SPN to recurrent lymphoma vs. new malignancy vs. benign change. PET Findings: SPN with increased uptake. Otherwise negative. Patient Treatment Management Change: Positive SPN, with no evidence of lymphoma elsewhere, justified surgery . Surgery proved that the nodule was in fact early stage low-grade lymphoma . This was different from the original histology which could be completely resected. Patient received their 3rd PET scan 8 months later: Following CT scan ...

Hematology 1999 329 Mantle Cell Lymphoma : New Treatment Possibilities Bertrand Coiffier Mantle cell lymphoma (MCL) represents one of the lym- phomas most refractory to treatment. Its initial presen- tation is characterized by a slow increase of lymph node volume, spleen size, and blood involvement making it a real indolent lymphoma . At diagnosis, most of the pa- tients have disseminated disease with enlarged lymph nodes, bone marrow and blood involvement, splenom- egaly, and often involvement of extranodal sites such as the colon or Waldeyer’s ring. The incidence of this lym- phoma is similar in the US and Europe, representing 8% of the non-Hodgkin’s lymphomas. Very few prospective clinical trials exist, making it impossible to define rec- ommendations for the treatment of these patients. More- over, the interpretation of the clinical trials or retrospec- ...

64. Oncologic Outcomes of Adult “Primary” Lymphoma of Bone *Valerae O. Lewis, M.D. Houston, TX Gregory Primus, M.D. Chicago, IL John Anastasi, M.D. Chicago, IL Anthony G. Montag, M.D. Chicago, IL Dorota Doherty, M.D. Houston, TX Terrance D. Peabody, M.D. Chicago, IL Michael A. Simon, M.D. Chicago, IL BACKGROUND: Lymphoma in bone is an uncommon entity. With contemporary imaging, staging, and treatment, primary lymphoma of bone is thought to have a good prognosis. We performed a retrospective analysis of patients who had lymphoma of bone to confirm or deny this impression, to determine with contemporary staging how many patients had stage IE, primary lymphoma of bone versus advanced lymphomatous disease, and to evaluate the prognostic factors and oncologic outcome of adult patients who have lymphoma of bone. METHOD: The records of 28 adult ...

Non-Hodgkin’s Lymphoma 70 CANCER INCIDENCE AND MORTALITY IN NEW MEXICO, 1970-1996 Major Epidemiologic Features Lymphomas are cancers of the white blood cells (lymphocytes) of the immune system. The disease process involves an abnormal growth of lymphocytes either within the lymph nodes or at extra-nodal sites such as the spleen and thymus. Non-Hodgkin’s lymphoma (NHL) refers to a diverse group of lymphomas that include many different histologic types, but exclude the cell types associated with Hodgkin’s disease, another form of lymphoma . NHL is a relatively common cancer, accounting for 4 to 5% of all cancers diagnosed in the U.S. each year. The incidence of NHL has increased dramatically over the past several decades in the U.S., roughly doubling between 1973 and 1995. Part of the increase in recent years has been related to the acquired immunodeficiency disorder (AIDS) epidemic. NHL is about 60 ...

Protection from Lymphoma Cell Metastasis in ICAM-1 Mutant Mice: A Posthoming Event Fawzi Aoudjit, 1 * Edouard F. Potworowski,* Timothy A. Springer, † and Yves St-Pierre 2 * It has been hypothesized that the intercellular adhesion receptors used by normal cells could also be operative in the spreading of circulating malignant cells to target organs. In the present work, we show that genetic ablation of the ICAM-1 gene confers resistance to T cell lymphoma metastasis. Following i.v. inoculation of LFA-1-expressing malignant T lymphoma cells, we found that ICAM-1-deficient mice were almost completely resistant to the development of lymphoid malignancy compared with wild-type control mice that developed lymphoid tumors in the kidneys, spleen, and liver. Histologic examinations confirmed that ICAM- 1-deficient mice, in contrast to wild-type ...

From the GRCA Health and Genetics Committee GOLDENS WITH LYMPHOMA AND OSTEOSARCOMA ARE NEEDED TO STUDY THE GENETIC BASIS OF LYMPHOMA AND OSTEOSARCOMA Most Golden Retriever fanciers know Goldens that have died of lymphoma (cancer of the lymph nodes, lymphosarcoma) and osteosarcoma (bone cancer). Since our Goldens are predisposed to these cancers, many of us have lost some of our own beloved Goldens to these diseases. The Canine Health Foundation has funded a study that may help determine the genetic basis of these cancers. We have hopes that this study and subsequent studies may some day lead to genetic tests to identify Goldens predisposed to developing lymphoma and bone cancer and may identify those lymphomas and bone cancers most likely to respond to treatment. If your Golden Retriever is newly diagnosed with lymphoma or osteosarcoma (has not yet started chemotherapy, including steroids), ...

Non-Hodgkin’s Lymphoma Highly Aggressive Aggressive Indolent B- Chronic lymphocytic leukemia Small lymphocytic lymphoma Lymphoplasmacytoid Follicular center cell grades I and II Marginal zone lymphoma B-Cell T-Cell B-Cell T-Cell Mantle cell lymphoma Follicular center cell grade III Diffuse large B-cell Primary mediastinal (thymic) large cell HIV associated B-Cell lymphomas Peripheral T-cell lymphoma Intestinal T-cell lymphoma Angiocentric lymphoma Angioimmunoblastic T-cell lymphoma Adult T-cell lmyphoma/leukemia Anaplastic Large cell B-cell Precursor B lymphoblastic lymphoma /leukemia Burkitt’s lymphoma T-cell Precursor T-lymphoblastic lymphoma /leukemia Adult T-cell leukemia/ lymphoma HTLV-1 T-Cell CLL/T-PLL Mycosis fungoides Non-Hodgkin’s ...

MOLECULAR ASSESSMENT OF GENE EXPRESSION IN B-CELL LYMPHOMA OF SIV INFECTED RHESUS MONKEYS ( MACACA MULATTA ). AN INTRODUC- TION. BODEMER, W., FLOTO, A., MÄTZ-RENSING, K. AND KAUP, F.-J. Key words: B-cell lymphoma , Simian immunodeficiency virus, HIV, oncogenic her- pesvirus, differential gene expression Abstract B-cell Non-Hodgkin’s lymphoma (B-NHL) is a typical tumor after infection with viruses causing immunodeficiency. Both, Simian as well as Human Immundeficien- cy Virus (SIV and HIV) are well known pathogens suspected to contribute to the de- velopment of B-cell lymphoma . Fortunately, macaques infected with SIV were shown to be an adequate non human primate model for NHL. In our group we established profound pathological examination protocols and identified classification markers. We conducted experiments to further insight into the molecular processes of lympho- magenesis. Presence of simian ...

In Touch 2001 ANNUAL REPORT mia- lymphoma .org www.leukemia- lymphoma .org www.leukemia- lymphoma .org www.leukemia- lymphoma .org www.leukemia- lymphoma .org www.leukemia- lymphoma .org www.leukemia- lymphoma .org www.leukemia Page 2 www.leukemia- lymphoma .org www.leukemia- lymphoma .org www.leukemia- lymphoma .org www.leukemia- lymphoma .org www.leukemia- lymphoma .org www.leukemia-lym ukemia- lymphoma .org www.leukemia- lymphoma .org w 5 On the cover: More than anything, 12-year-old Kati Fisher wanted to be in San Diego when the Maryland Chapter’s Team In Training ® members participated in the 2001 Suzuki ® Rock ‘n’ Roll Marathon. ® Last June, Kati, an acute lymphocytic leukemia patient, was one of the first to greet Cliff Walzer, a non-Hodgkin’s ...

Follicular Lymphoma Toronto-Sunnybrook Regional Cancer Centre Hematology Site Group - Treatment Policies 1/10 Follicular Lymphoma Treatment policy prepared by Dr. Louise Bordeleau 1. Introduction Follicular lymphoma is the second most frequent type of non-Hodgkin’s lymphoma . These lymphomas are classified as follicular small cleaved cell, follicular mixed cell and follicular large cell lymphoma in the Working Formulation [1]. According to the WHO classification, this entity is classified as follicle center cell lymphoma , follicular grade 1 (small cleaved cell), grade 2 (mixed small and large cell) and grade 3 (large cell) [2]. 2. Diagnosis The diagnosis of follicular lymphoma is dependent on an adequate biopsy specimen (preferable open surgical biopsy) with immunohistochemistry. This lymphoma is composed of ...

68 NATURE MEDICINE • VOLUME 8 • NUMBER 1 • JANUARY 2002 A RT I C L E S Diffuse large B-cell lymphomas (DLBCLs) are the most common lymphoid neoplasms, composing 30–40% of adult non-Hodgkin lymphomas 1 . Although a subset of DLBCL patients are cured with current chemotherapeutic regimens, most succumb to the disease 2 . Clinical prognostic models such as the International Prognostic Index (IPI) have been developed to identify DLBCL patients who are unlikely to be cured with standard therapy 3 . However, the clinical factors of the IPI (age, performance status, stage, number of extranodal sites and serum lactate dehydroge- nase (LDH)) 3 are likely to be surrogate markers for the intrinsic molecular heterogeneity in this disease. Therefore, it is not sur- prising that IPI is imperfect in its identification of high-risk pa- ...

1 Supplementary Information for DIFFUSE LARGE B-CELL LYMPHOMA OUTCOME PREDICTION BY GENE EXPRESSION PROFILING AND SUPERVISED MACHINE LEARNING Margaret A. Shipp, Ken N. Ross, Pablo Tamayo, Andrew P. Weng, Jeffery L. Kutok, Ricardo C. T. Aguiar, Michelle Gaasenbeek, Michael Angelo, Michael Reich, Geraldine S. Pinkus, Tane S. Ray, Margaret A. Koval, Kim W. Last, Andrew Norton, T. Andrew Lister, Jill Mesirov, Donna S. Neuberg, Eric S. Lander, Jon C. Aster, and Todd R. Golub December 6, 2001 Contents: Section I: Expanded Methods __ 3 Primary Lymphoma Specimens and Clinical Information _ 3 Microarray Hybridization _ 3 Preprocessing and Re-scaling _ 4 Supervised Learning4 Gene Marker Selection_ 5 Permutation Test and Neighborhood Analysis for Marker Genes _ 5 Algorithms__ 9 Weighted Voting 9 k-Nearest Neighbors (KNN) 9 ...

Journal of Neurological Sciences (Turkish) Table of Contents NOROL BIL D 18: 4 , 2001 http://www.med.ege.edu.tr/norolbil/2001/NBD17501.html Case Report POLYNEUROPATHY ASSOCIATED WITH IgM PARAPROTEINEMIA IN A NON-HODGKIN LYMPHOMA PATIENT A case report Basar BILGIÇ , Baris BASLO , Mürrüvvet POYRAZ , A. Emre OGE , Jale YAZICI Istanbul University, Istanbul School of Medicine, Department of Neurology , Çapa , Istanbul , 34990 , Turkey SUMMARY We report a patient with B-cell Non-Hodgkin lymphoma who had polyneuropathy, cranial nerve involvement , systemic symptoms and paraproteinemia. The patient had subacute onset of polyneuropathy symptoms which were asymmetric, involves the left upper and right lower limbs more severely, most predominantly motor findings and meningeal irritation signs. Electrophysiologic studies revealed severe impairment ...